There was also significantly less worsening in the hematology BILAG domain and a favorable trend in the vasculitis and renal domains. 29 Significant improvements were seen in both belimumab groups of BLISS-52 in the SFI flare rate and time to first flare, although the severe SFI flare rate and the rate of new BILAG 1A/2B scores at 52 weeks were significantly reduced only in the 10 mg/kg belimu
1
—
—